Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
about
Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance PredictionSusceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Achieving target voriconazole concentrations more accurately in children and adolescents.Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia.Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.Successful long-term management of invasive cerebral fungal infection following liver transplantation.A new marker of echinocandins activity in an in vitro PK/PD model correlates with an animal model of Aspergillus fumigatus infection.Evolution of cross-resistance to medical triazoles in Aspergillus fumigatus through selection pressure of environmental fungicides.
P2860
Q26753831-1A79A0D0-85F6-4B6C-BDE6-61100DE93D64Q33622932-86D154F3-1C51-4A1B-BC81-690C684AAA49Q34532546-49067702-2DC4-44AB-A538-8F019E321477Q35607652-055CD589-F9F6-4D96-9578-E0790AAB36ACQ35746264-6499B3F3-2CB7-4321-B9B6-FCCB40F9C900Q36696390-CC556F49-D93E-4586-8662-F8376FBB8D8FQ38362057-B9B13969-84B2-4F29-9B34-DD00E99930E3Q40587101-098582DA-E297-4512-AE7A-E45C64FA08DDQ41543346-01060D34-3B66-4E7D-85A5-EC3386936CACQ49792124-A7C469DF-D9B1-4BE5-9B53-6E6BD8DB729EQ53725145-973952DB-83B9-44EF-B788-B9FF439E5719
P2860
Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@en
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@nl
type
label
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@en
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@nl
prefLabel
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@en
Susceptibility breakpoints and ...... kinetic/pharmacodynamic model.
@nl
P2093
P2860
P356
P1476
Susceptibility breakpoints and ...... okinetic/pharmacodynamic model
@en
P2093
Eleftheria Mavridou
Johan W Mouton
Joseph Meletiadis
Loukia Zerva
Maria Siopi
P2860
P304
P356
10.1093/JAC/DKU023
P407
P577
2014-02-17T00:00:00Z